Skip directly to page options Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research Letter

SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

Seonju Yi1, Young June Choe1, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, and Young-Joon ParkComments to Author 
Author affiliations: Korea Disease Control and Prevention Agency, Cheongju, South Korea (S. Yi, J. Kim, Y.-Y. Kim, R.K. Kim, E.J. Jang, D.S .Lim, H.R. Byeon, S. Lee, E. Park, S.-J. Kim, Y.-J. Park); Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe)

Main Article

Figure

Age-specific breakthrough infection rates (cases/100,000 population) of severe acute respiratory syndrome coronavirus 2 for 4 vaccines by vaccine type, South Korea. A) ChAdOx1 nCov-19 (AstraZeneca prime/booster), April–October 2021. B) BNT162b2 (Pfizer-BioNTech prime/booster), April–October 2021. C) Ad26.COV2.S (Johnson & Johnson/Janssen, single dose), June–October 2021. D) mRNA-1273 (Moderna, prime/booster), July–October 2021. E) ChAdOx1 nCov-19/BNT162b2(AstraZeneca prime/Pfizer-BioNTech booster), July–October 2021.

Figure. Age-specific breakthrough infection rates (cases/100,000 population) of severe acute respiratory syndrome coronavirus 2 for 4 vaccines by vaccine type, South Korea. A) ChAdOx1 nCov-19 (AstraZeneca prime/booster), April–October 2021. B) BNT162b2 (Pfizer-BioNTech prime/booster), April–October 2021. C) Ad26.COV2.S (Johnson & Johnson/Janssen, single dose), June–October 2021. D) mRNA-1273 (Moderna, prime/booster), July–October 2021. E) ChAdOx1 nCov-19/BNT162b2(AstraZeneca prime/Pfizer-BioNTech booster), July–October 2021.

Download

Main Article

1These authors contributed equally to this article.

Page created: February 08, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external